Moderna is now expecting 2025 research and development costs of about $4.1 billion and selling, general and administrative costs of about $1.1 billion. Cost of sales is expected to come to about $1.2 ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

The U.S. has seen earlier and more intense surges of the flu and RSV this year than is typical, pediatrician Dr. Ryan Fulton ...

Babies under 8 months old are eligible to get an RSV vaccine, and women who are pregnant can also get it to protect kids before they're born. The vaccine is available now through March. If you have ...

Says a pediatric infectious disease physician, “Our expectation is that we’re going to have several more weeks yet of a lot ...

Increase in ER Visits, Hospital Admissions is Driven by Flu; IDPH Urges Public To Quickly Seek Testing and Treatment if they Experience Flu-like Symptoms The Illinois Department of Public Health (IDPH ...

Reports Q1 revenue $17M, consensus $17.25M. “2025 is primed to be a pivotal year for Enanta (ENTA) as we execute on multiple catalysts across ...

Understand RA from early to advanced stages. Explore symptoms, treatments, and lifestyle tips to manage rheumatoid arthritis ...

Scientists have discovered something that happens during human development that might be able to explain why some people are ...

‘Are bacteria making #RSV infections worse in kids? Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, ...

“Areas with lower vaccination rates, colder weather and higher population density are seeing higher infection rates,” said Dr ...

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections in children under two years old, resulting in significant morbidity and a heavy economic burden on healthcare ...